Last Price
19.51
Today's Change
-32.189 (62.26%)
Day's Change
17.00 - 23.10
Trading Volume
12,174,945
Market Cap
234 Million
Shares Outstanding
12 Million
Avg Volume
482,700
Avg Price (50 Days)
54.98
Avg Price (200 Days)
37.05
PE Ratio
-3.37
EPS
-5.79
Earnings Announcement
05-Nov-2024
Previous Close
51.70
Open
17.72
Day's Range
17.0 - 23.1
Year Range
3.033 - 61.9
Trading Volume
12,240,765
1 Day Change
-62.26%
5 Day Change
-65.26%
1 Month Change
-68.30%
3 Month Change
-54.07%
6 Month Change
-48.86%
Ytd Change
208.21%
1 Year Change
200.15%
3 Year Change
-35.61%
5 Year Change
-87.66%
10 Year Change
-78.32%
Max Change
-78.32%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.